Insider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Purchases 3,180 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim acquired 3,180 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were acquired at an average cost of $13.36 per share, for a total transaction of $42,484.80. Following the purchase, the director now directly owns 56,074 shares in the company, valued at approximately $749,148.64. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Entrada Therapeutics Trading Up 4.3 %

TRDA stock opened at $14.35 on Thursday. The stock has a 50-day moving average price of $13.84 and a two-hundred day moving average price of $14.54. Entrada Therapeutics, Inc. has a 1 year low of $10.62 and a 1 year high of $18.44.

Analyst Upgrades and Downgrades

Several analysts recently commented on TRDA shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research note on Monday, March 18th. Oppenheimer started coverage on Entrada Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $22.00 price objective on the stock.

Hedge Funds Weigh In On Entrada Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in Entrada Therapeutics by 12.5% during the 1st quarter. JPMorgan Chase & Co. now owns 8,540 shares of the company’s stock worth $124,000 after purchasing an additional 947 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Entrada Therapeutics by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 88,970 shares of the company’s stock worth $1,203,000 after purchasing an additional 1,111 shares in the last quarter. Bank of America Corp DE increased its holdings in Entrada Therapeutics by 33.5% during the 4th quarter. Bank of America Corp DE now owns 5,296 shares of the company’s stock worth $72,000 after purchasing an additional 1,330 shares in the last quarter. Swiss National Bank increased its holdings in Entrada Therapeutics by 6.3% during the 2nd quarter. Swiss National Bank now owns 25,200 shares of the company’s stock worth $382,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Entrada Therapeutics by 18.0% during the 3rd quarter. Deutsche Bank AG now owns 10,038 shares of the company’s stock worth $159,000 after purchasing an additional 1,532 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.